Mounjaro (often misspelled “Manjaro”) is a once-weekly injectable medication containing tirzepatide, a drug that targets two gut hormones involved in appetite and blood sugar regulation. It’s FDA-approved for type 2 diabetes, not weight loss specifically, but it produces significant weight loss as a major secondary effect. In clinical trials, people lost between 15% and 21% of their body weight over 72 weeks depending on dose. A separate brand of the same drug, called Zepbound, is the version officially approved for weight management in people without diabetes.
How Mounjaro Works
Tirzepatide is a dual-action drug, meaning it activates two different receptor systems in your body at the same time. Most weight loss injections like semaglutide (Ozempic, Wegovy) target only one of these systems. Mounjaro targets both: the GLP-1 receptor and the GIP receptor. Together, these signals slow stomach emptying, reduce appetite, improve how your body responds to insulin, and change how your brain processes hunger cues.
The GIP receptor component appears to do something that GLP-1 alone doesn’t. It improves insulin sensitivity through a mechanism that’s independent of weight loss itself, which may explain why tirzepatide outperforms single-target drugs for both blood sugar control and body weight reduction. The way tirzepatide activates the GLP-1 receptor is also unusual. It causes less receptor burnout than the body’s own GLP-1 hormone does, which may help sustain the drug’s effects over time rather than diminishing them.
Mounjaro vs. Zepbound: Same Drug, Different Labels
This distinction confuses a lot of people. Mounjaro and Zepbound contain the exact same active ingredient, tirzepatide, at the same doses. The difference is purely regulatory. Mounjaro is approved for adults with type 2 diabetes to improve blood sugar control. Zepbound is approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol, or obstructive sleep apnea.
When doctors prescribe Mounjaro “off-label” for weight loss in someone without diabetes, they’re using the diabetes-approved version for a purpose the FDA hasn’t formally signed off on. This is legal and common, but it can affect insurance coverage. If your goal is weight loss and you don’t have type 2 diabetes, Zepbound is the version your insurance is more likely to cover.
How Much Weight People Lose
The landmark SURMOUNT-1 trial tested tirzepatide in adults with obesity who did not have diabetes. Over 72 weeks (about a year and a half), participants lost an average of 15% of their body weight on the 5 mg dose, 19.5% on the 10 mg dose, and 20.9% on the 15 mg dose. The placebo group lost 3.1%. For context, a person weighing 250 pounds on the highest dose would lose roughly 52 pounds on average.
When compared head-to-head against semaglutide (the active ingredient in Wegovy and Ozempic), tirzepatide came out ahead. In the SURMOUNT-5 trial, tirzepatide produced 47% greater weight loss overall: participants lost an average of 50.3 pounds compared to 33.1 pounds with semaglutide. Waist circumference dropped by 7.2 inches with tirzepatide versus 5.1 inches with semaglutide. Earlier trials in people with type 2 diabetes showed a similar gap, with tirzepatide at various doses producing 17 to 25 pounds of weight loss compared to 13 pounds for semaglutide.
Dosing and What to Expect
Mounjaro is injected once a week using a prefilled pen, similar to an insulin pen. You inject it into your abdomen, thigh, or upper arm, rotating the site each week. The starting dose is 2.5 mg, which is intentionally low to let your body adjust. After four weeks, the dose increases to 5 mg. From there, your doctor can raise it in 2.5 mg steps every four weeks or longer, up to a maximum of 15 mg per week for adults.
Most people don’t notice dramatic appetite changes at the 2.5 mg starting dose. That phase is really about minimizing side effects. The appetite suppression and weight loss typically become noticeable once you reach 5 mg or higher. The full titration to the maximum dose takes at least 20 weeks if you increase at every opportunity, though many people stay at a mid-range dose if they’re responding well and tolerating it without problems.
Side Effects
The most common side effects are gastrointestinal. In clinical trials, 30% to 40% of people experienced nausea, 20% to 25% had diarrhea, 15% to 18% reported vomiting, and 12% to 15% dealt with constipation. These effects tend to be worst during dose increases and often improve after a few weeks at a stable dose. Eating smaller meals, avoiding high-fat foods, and eating slowly can help manage the nausea.
There is a boxed warning on the label regarding thyroid cancer. In animal studies, tirzepatide caused thyroid tumors. It’s unknown whether this applies to humans, but Mounjaro is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you have a lump or swelling in your neck, hoarseness, or difficulty swallowing while taking the medication, those symptoms warrant prompt medical attention.
What Happens If You Stop
Weight regain after stopping tirzepatide is a real concern and one of the most important things to understand before starting. A 2025 systematic review published in The BMJ found that people regain weight at an average rate of about 0.9 pounds per month after stopping incretin-based medications. Within the first year off the drug, people who had been on newer, more effective medications like tirzepatide regained an estimated 22 pounds. The review projected that most people would return to their original weight within roughly a year and a half of stopping treatment.
Cardiometabolic improvements, such as better blood pressure, blood sugar, and cholesterol levels, also reversed within about 1.4 years of stopping. Notably, weight regain after medication was faster than weight regain after behavioral programs like structured diet and exercise interventions, by about 0.7 pounds more per month. This doesn’t mean lifestyle changes are unnecessary on the medication. It means that for most people, tirzepatide works best as a long-term treatment rather than a short course.
Who Is a Good Candidate
For the diabetes indication (Mounjaro), candidates are adults with type 2 diabetes who need better blood sugar control alongside diet and exercise. For weight management (Zepbound), candidates are adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. People with a history of pancreatitis, severe gastrointestinal disease, or the thyroid conditions mentioned above are generally not good candidates.
Tirzepatide is not a cosmetic weight loss tool for people at a healthy weight. The clinical trials enrolled people with significant excess weight, and the risk-benefit calculation changes substantially for someone who only wants to lose a small amount. The gastrointestinal side effects, the cost (which can exceed $1,000 per month without insurance), and the likelihood of regain after stopping all factor into whether this medication makes sense for your situation.